BresaGen signs two new contracts
Tuesday, 02 August, 2005
Adelaide-based BresaGen (ASX:BGN) has signed two new contracts under its protEcol Services business unit.
The first is with Irish based Opsona Therapeutics, which will use BresaGen to progress process development of its pre-clinical immunomodulator, OPN-201. The second contract is with US firm Pepgen Corporation, which first partnered with BresaGen in 2004, to develop a process for Pepgen to produce a novel interferon alpha analog, Neoferon.
Under the contract, BresaGen will further develop the E. coli-based process and produce GLP recombinant protein.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
